Related Experiment Video
Updated: Apr 3, 2026

09:19
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
Published on: July 14, 2022
4.6K
Robotic-Modified Taj Mahal Hepatectomy for Type IV Hilar Cholangiocarcinoma
Raja Kalayarasan1, Pothugunta Sai Krishna2, Damalapati Venkatesh2
1Department of Surgical Gastroenterology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry, India. kalayarasanraja@yahoo.com.
Annals of Surgical Oncology
|April 1, 2026
Summary
Robotic-modified Taj Mahal hepatectomy offers a safe, parenchyma-preserving approach for hilar cholangiocarcinoma. This minimally invasive technique demonstrates feasibility and positive outcomes in selected patients.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Minimally Invasive Surgery
Background:
- Type IV hilar cholangiocarcinoma resection often requires extensive liver resection (trisectionectomy), leading to high morbidity.
- The traditional Taj Mahal hepatectomy involves resection of segments IVb, V, and the caudate lobe.
- A modified approach focusing on segment IV and caudate lobe resection preserves more parenchyma.
Purpose of the Study:
- To describe the standardized technique of robotic-modified Taj Mahal hepatectomy for type IV hilar cholangiocarcinoma.
- To report the initial outcomes of this minimally invasive approach.
Main Methods:
- The procedure involves hepatoduodenal lymphadenectomy, bile duct division, caudate lobe mobilization, and segment IV resection with en bloc caudate lobectomy.
- Indocyanine green (ICG) is used for guidance during segment IV resection.
- Robotic platform facilitates precise dissection and reconstruction.
Main Results:
- The study included four patients over 12 months, with one detailed case presented.
- The described case had an operative time of 560 minutes and 300 mL blood loss.
- The patient achieved negative margins, recovered uneventfully, and remained disease-free at 11-month follow-up.
Conclusions:
- Robotic-modified Taj Mahal hepatectomy is a safe and feasible parenchyma-preserving option.
- This approach is suitable for selected patients with type IV hilar cholangiocarcinoma.
- Further studies are warranted to evaluate long-term outcomes.

